{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.7","upperLimit":"15.9","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Defined as the time from treatment initiation until disease progression, death, or last follow-up. Will be summarized using standard Kaplan-Meier methods; where estimates of median survival and survival rates will be obtained with 90% confidence intervals.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAbatacept: Given IV and SC\n\nDexamethasone: Given PO\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Abatacept, Ixazomib Citrate, Dexamethasone)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the date of the first study treatment to the date of first observed disease progression or death due to any cause, assessed up to 5 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}